By utilizing biochemical analysis, Access Bio has successfully developed the world’s first point-of-care glucose-6-phosphate dehydrogenase (G6PD) deficiency test, CareStart™ G6PD RDT. CareStart™ G6PD RDT is a companion diagnostics for safe use of primaquine, a drug that kills gametocytes and hypnozoites of Plasmodium falciparum and P. vivax, respectively. When G6PD deficient malaria patients take primaquine, they may experience acute anemia due to hemolysis. This side-effect can be life threatening and thus should be avoided. Unlike currently widely used fluorescent spot tests that need refrigeration of reagents and UV lamp to see the result, CareStart™ G6PD RDT requires no additional equipment to screen for G6PD deficiency and the result can be read through the naked eye within 10 minutes. CareStart™ G6PD RDT is a true point-of-care product that is suitable in many malarious regions and it demonstrated over 95% sensitivity for Class I or II G6PD deficiency samples in several clinical studies.
While CareStart™ G6PD RDT is a qualitative test determining if a patient is severely deficient for G6PD enzymes or not (i.e., Class I and II cases), CareStart™ G6PD Biosensor is a quantitative test that can measure total G6PD enzyme activity in whole blood in just 4 minutes. Therefore, CareStart™ G6PD Biosensor can screen for severe G6PD deficiency and determine a whole range of the enzyme activities quantitatively. Because G6PD deficiency is an inheritable genetic disorder, CareStart™ G6PD Biosensor is ideal for newborn screening in countries where G6PD deficiency is prevalent. Like CareStart™ G6PD RDT, CareStart™ G6PD Biosensor is the world’s first product of its kind.
|Product Pipeline||G6PD RDT|